Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease

Japan approves Lundbeck's eptinezumab for preventive migraine treatment

Jubilant Therapeutics reports preliminary clinical data from Phase 1/2 study in myeloproliferative neoplasms at SOHO 2026

Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease

GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma

Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer

FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis

Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02

AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial

GSK reports positive Jideytro data supporting potential first-line lung cancer use

Eloxx Pharmaceuticals commences Phase 2b study of exaluren

Akeso presents positive results from registrational Phase III study of ivonescimab

FDA grants Priority Review to Genentech's Enspryng for MOGAD

BioMarin announces positive Phase 3 VOXZOGO (vosoritide) study results in hypochondroplasia published in NEJM Evidence

Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock